Agilent Technologies, Inc.

The rising demand for prostate cancer diagnostics is mainly driven by the growing incidence of the disease, heightened awareness and screening initiatives, and ongoing advancements in diagnostic technologies, projected for the period from 2024 to 2030. LAS VEGAS, Sept. 25, 2024 /PRNewswire/ -- DelveInsight's Prostate Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading prostate cancer diagnostics companies' market shares, challenges, prostate cancer diagnostics market drivers, barriers, trends, and key market prostate cancer diagnostics companies in the market. Key Takeaways from the Prostate Cancer Diagnostics Market Report As per DelveInsight estimates, North America is anticipated to dominate the global prostate cancer diagnostics market during the forecast period. In the test type segment of the prostate cancer diagnostics market, the imaging tests category had a significant revenue share in the prostate cancer diagnostics market in 2023. Notable prostate cancer diagnostics companies such as F. Hoffmann-La Roche Ltd, Myriad Genetics, Inc., Abbott., MDx Health, Siemens Healthcare, OPKO Health, Inc., Genomic Health, Inc., Agilent Technologies, Inc., BD., BIOCEPT, INC., Proteomedix, A3P Biomedical AB, GE HealthCare., Soteria Medical BV, Bio-Techne., Indica Labs, Inc., miR Scientific, MINOMIC®, ACON Laboratories, Inc., Hologic, Inc., and several others, are currently operating in the prostate cancer diagnostics market. In September 2023, MDxHealth announced a research collaboration with the University of Oxford to investigate the correlation between the Genomic Prostate Score (GPS) test and prostate cancer progression following treatment for localized prostate cancer. In July 2023, Quest Diagnostics launched the novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences. Envision Sciences Pty Ltd. is an Australian-based clinical diagnostics company developing a pipeline of biomarker-based cancer diagnostic and prognostic tests in tissue and blood. To read more about the latest highlights related to the prostate cancer diagnostics market, get a snapshot of the key highlights entailed in the Global Prostate Cancer Diagnostics Market Report Prostate Cancer Diagnostics Overview Prostate cancer diagnostics involve a combination of tests and procedures aimed at detecting the presence of cancerous cells in the prostate gland. The initial step typically includes a digital rectal examination (DRE), where a physician physically examines the prostate for abnormalities. However, the most definitive diagnostic tool is the prostate-specific antigen (PSA) blood test, which measures the level of PSA, a protein produced by the prostate. Elevated PSA levels can indicate prostate cancer, though they can also be due to other conditions such as benign prostatic hyperplasia (BPH) or prostatitis. If initial tests suggest the possibility of cancer, further diagnostic procedures are often employed. A prostate biopsy, usually guided by transrectal ultrasound (TRUS), involves taking small tissue samples from the prostate to be examined microscopically for cancer cells. Imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, can provide detailed views of the prostate and surrounding tissues to assess the extent of the cancer and aid in staging. Together, these diagnostic tools help to accurately identify prostate cancer, determine its aggressiveness, and guide appropriate treatment strategies. Prostate Cancer Diagnostics Market Insights In 2023, North America held the largest share of the prostate cancer diagnostics market compared to other regions. This dominance is largely due to the high incidence of prostate cancer, the growing elderly population, and the region's advanced diagnostic infrastructure. North America's sophisticated healthcare system, featuring cutting-edge hospitals, diagnostic centers, and research facilities, facilitates accurate and timely prostate cancer diagnoses through state-of-the-art imaging technologies like multiparametric MRI (mpMRI) and advanced laboratory testing. Additionally, North America's public health initiatives, advocacy efforts, and healthcare policies bolster prostate cancer awareness and promote regular screening among at-risk individuals. These initiatives, including the Canadian Cancer Society's Prostate Cancer Awareness Month in September, enhance early detection rates and diagnostic testing uptake. As a result, the increasing prevalence of prostate cancer and the region's high-quality healthcare infrastructure, combined with growing government awareness efforts, are expected to significantly drive the prostate cancer diagnostics market in North America throughout the forecast period. To know more about why North America is leading the market growth in the prostate cancer diagnostics market, get a snapshot of the Prostate Cancer Diagnostics Market Outlook Prostate Cancer Diagnostics Market Dynamics The prostate cancer diagnostics market is witnessing significant growth, driven by the i ncreasing prevalence of prostate cancer and advancements in diagnostic technologies. As one of the most common cancers affecting men globally, the need for early and accurate diagnosis has spurred innovation. Traditional diagnostic methods, such as prostate-specific antigen (PSA) testing, have faced criticism for their lack of specificity, leading to false positives and unnecessary biopsies. This has created a demand for more reliable, non-invasive, and precise diagnostic tools, contributing to the expansion of this market. Emerging diagnostic technologies, including liquid biopsies, genomic testing, and advanced imaging techniques, are gaining prominence. Liquid biopsies, for instance, offer a minimally invasive method to detect genetic mutations and monitor disease progression through blood samples. This approach is more patient-friendly and allows for continuous monitoring, unlike traditional biopsies. Genomic testing, on the other hand, enables personalized treatment strategies by identifying specific genetic markers linked to aggressive forms of prostate cancer. These innovations are helping clinicians make more informed decisions, thus improving patient outcomes and driving market growth. The rise of artificial intelligence (AI) and machine learning in medical diagnostics is another key factor influencing the prostate cancer diagnostics market. AI-driven platforms are being developed to enhance the accuracy of imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) scans. These systems can analyze complex data more efficiently, helping radiologists detect early-stage cancer with greater precision. Moreover, AI can assist in interpreting results from genomic and biomarker tests, reducing human error and speeding up diagnosis. The integration of AI in prostate cancer diagnostics is expected to further propel market expansion. However, despite these positive trends, the prostate cancer diagnostics market faces challenges. High costs associated with advanced diagnostic technologies, limited access to healthcare in certain regions, and the potential for overtreatment are key concerns. Nonetheless, ongoing research and development, coupled with growing collaborations between pharmaceutical companies and diagnostic tool developers, are likely to address these challenges and create lucrative opportunities for future growth in the market. Get a sneak peek at the prostate cancer diagnostics market dynamics @ Prostate Cancer Diagnostics Market Dynamics Analysis Prostate Cancer Diagnostics Market Assessment Prostate Cancer Diagnostics Market Segmentation Prostate Cancer Diagnostics Market Segmentation By Test Type: Imaging Tests, Biomarker Tests, Biopsy, Immunohistochemistry, and Others Prostate Cancer Diagnostics Market Segmentation By End User: Hospitals & Clinics, Diagnostic Centers, Research & Academics, and Others Prostate Cancer Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the prostate cancer diagnostics market are set to emerge as the trendsetter explore @ Prostate Cancer Diagnostics Companies Table of Contents Interested in knowing the prostate cancer diagnostics market by 2030? Click to get a snapshot of the Prostate Cancer Diagnostics Market Trends Related Reports Prostate Cancer Market Prostate Cancer Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key prostate cancer companies, including Proteomedix, A3P Biomedical, GE HealthCare, Soteria Medical BV, Bio-Techne, F. Hoffmann-La Roche Ltd., Indica Labs Inc., OPKO HEALTH, INC., miR Scientific, LLC, MINOMIC®, Novartis AG, Johnson and Johnson Services, Inc., Astellas Pharma Inc., Cipla, AstraZeneca, Bayer AG, Zydus Cadila, Pfizer Inc., Avenda Health, The Sanpower Group, among others. Metastatic Prostate Cancer Market Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others. Metastatic Castration-Resistant Prostate Cancer Market Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic castration-resistant prostate cancer companies including AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Janssen Research & Development, Tesaro, Modra Pharmaceuticals, AB Science, Essa Pharma, Eli Lilly and Company, Zr Pharma & GmbH, Bristol-Myers Squibb, Novartis, Ipsen, Exelixis, Takeda, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Bayer, Arvinas, Novartis, Point Biopharma, Xencor among others. Metastatic Castration-Sensitive Prostate Cancer Market Metastatic Castration-Sensitive Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCSPC companies including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Nearly 300 of Masimo’s engineers and global managers, as well as its COO, signed public letters saying they would resign if founder Kiani was removed from the board. Masimo’s long-running proxy fight has come to a close, at least for now. During the company’s annual meeting, shareholders elected two board members nominated by activist investor Politan Capital Management—and ousted the medtech’s founder and CEO, Joe Kiani, in the process.Politan’s gains double the two board seats it claimed last year, with the June 2023 election of the firm’s managing partner, Quentin Koffey, as well as Michelle Brennan, a former executive at Johnson & Johnson, amid criticism of Masimo’s $1 billion purchase of the consumer audio group Sound United.This time around, Politan—which holds about a 9% stake in the maker of pulse oximeters and other patient monitors—decried the company’s plans to spin out its consumer businesses, including that home audio equipment as well as its high-tech baby monitor systems and health-focused smartwatches. Koffey and Brennan—along with the two newly appointed members, Darlene Solomon and William Jellison—issued a joint statement after the meeting: “While each of us is independent and brings our own unique perspectives, we are united in our enthusiasm for Masimo’s future as a leading, innovation-focused growth company.”“We look forward to meeting with, learning from, and working together with the Healthcare and Consumer employees to make Masimo an even greater company. We would also like customers to know that we will be completely focused on preventing any disruption to their service and support,” they added. “We will have more to share soon.”Solomon spent 39 years at Agilent, including as chief technology officer and senior VP, while Jellison previously served as chief financial officer at Stryker. According to a report by CNBC, Politan’s nominees received about twice as many votes as Kiani and also-ousted board member Chris Chavez, formerly CEO of Trivascular and Advanced Neuromodulation Systems. Masimo’s stock price rose about 3.4% after the vote, to over $115 per share. While Kiani said that he would quit his position and sell his company shares if the vote didn’t go his way, he may not be alone in walking out the door.Nearly 300 of Masimo’s engineers and global managers signed onto public letters saying they would do the same while Chief Operating Officer Bilal Muhsin tendered a conditional resignation letter in late June. Previously, Politan had said it would not oppose the reelection of Kiani to an expanded board.

None Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren Incorvaia or Gabrielle Masson and it will be featured here at the end of each week.2 Kite vets fly over to Kyverna TherapeuticsKyverna Therapeutics Warren Biddle hit the exit from his role as SVP, global head of commercial at Gilead Sciences' CAR-T unit Kite Pharma to take on the CEO gig at fellow CAR-T maker Kyverna, effective immediately. The new CEO succeeds Peter Maag, Ph.D., who resigned after two years at the helm. After starting at Kite in 2020 following a decade at Genentech, Biddle served as Kite’s interim CEO when its former head Christi Shaw, who is also joining Kyverna as a member of the board, departed in 2023. Shaw replaces Brian Kotzin, M.D., who opted to step down. ReleaseEyconis eyes Big Pharma vet as CEOEyconis Inc.Eyconis, a biotech with its sights on treating eye diseases, has secured former Amgen and Bristol Myers Squibb leader Mark Bachleda as its new CEO. Bachleda most recently served as chief commercial officer at Galera Therapeutics and before that served in top roles at BMS, Amgen and Juno Therapeutics. He started his career at other top pharmas Pfizer and Johnson & Johnson. Eyconis was launched at the beginning of the year by Ascendis Pharma and Frazier Life Sciences and was previously led by co-founder Emmett Cunningham, M.D., Ph.D., as executive chairman, a position he will still hold. ReleaseStructure reinforces exec team with promotion and hireStructure TherapeuticsStructure, a biotech with an oral small molecule GLP-1 agonist set to enter a phase 2 trial later this year, is building up its leadership team in preparation. Blai Coll, M.D., Ph.D., is replacing Mark Bach, M.D., Ph.D., as chief medical officer, while Ashley Hall is the company’s first chief development officer. Coll was previously Structure’s vice president of endocrine and metabolism clinical development, while Hall is joining from Reneo Pharmaceuticals, where she served as CDO. Release> Karen Knudsen, Ph.D., will step down from her role as CEO at the American Cancer Society and the affiliated American Cancer Society Cancer Action Network, leaving the organization’s board to begin a national search for a new CEO before the end of the year. Release> IMU Biosciences appointed Jason Brown, Ph.D., as CFO and Abcam vet John Baker as CEO, while current CEO Adam Laing, Ph.D., will stay on board as president and chief scientific officer. Release> Abata Therapeutics’ chief technical officer Stephen Sofen, Ph.D., is retiring and passing the torch to seasoned executive Joanne Beck, Ph.D. Release> With its lead candidate in phase 3 development, 89bio looped in Teresa Perney, Ph.D., as its new chief regulatory and quality officer. Release> Ochre Bio’s co-founder and CEO Jack O’Meara is bidding adieu to the company, leaving Eliot Forster, Ph.D., in the executive chairman role during the interim. Announcement> Nura Bio promoted chief scientific officer and founding member Shilpa Sambashivan, Ph.D., to the CEO role as it prepares to take its lead asset into a phase 1b/2 study. Release> Kentaro (Ken) Suzuki is leaving Agilent Technologies and taking his mass spectrometry expertise with him to join Nautilus Biotechnology, a company developing techniques to quantify the proteome, as chief marketing officer. Release> Precision medicine firm Entact Bio has appointed Ruben Tommasi, Ph.D., as chief scientific officer to help it in its mission of enhancing the function of beneficial proteins. Release> HotSpot Therapeutics is bringing Alison O’Neill, M.D., on board from Surface Oncology to be its new chief medical officer. Release> Investment firm Frazier Life Sciences is adding seasoned company founder Adam Simpson, whose most recent company Icosavax was acquired by AstraZeneca, to their company creation team as a venture partner. Release> John Beeler, Ph.D., is taking the leap from BMS to BPGbio, where he’ll serve as senior vice president of business development. Release